[go: up one dir, main page]

ES2166915T3 - N-acil-4-piperidinas sustituidas en posicion 2 que tienen restos sustituidos con bencimidazolilo o imidazopiridinilo, como antagonistas de la taquiquinina. - Google Patents

N-acil-4-piperidinas sustituidas en posicion 2 que tienen restos sustituidos con bencimidazolilo o imidazopiridinilo, como antagonistas de la taquiquinina.

Info

Publication number
ES2166915T3
ES2166915T3 ES96944686T ES96944686T ES2166915T3 ES 2166915 T3 ES2166915 T3 ES 2166915T3 ES 96944686 T ES96944686 T ES 96944686T ES 96944686 T ES96944686 T ES 96944686T ES 2166915 T3 ES2166915 T3 ES 2166915T3
Authority
ES
Spain
Prior art keywords
replaced
rent
corresponds
optionally replaced
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96944686T
Other languages
English (en)
Inventor
Frans Eduard Janssens
Francois Maria Sommen
Dominique Louis Nes Surlerraux
Joseph Elisabeth Leenaerts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26139977&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2166915(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2166915T3 publication Critical patent/ES2166915T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

ESTA INVENCION ESTA RELACIONADA CON UNOS COMPUESTOS CON LA FORMULA (I), SUS FORMAS N OXIDO, SUS SALES DE ADICION FARMACEUTICAMENTE ACEPTABLES Y SUS FORMAS ESTEREOQUIMICAMENTE ISOMERICAS DERIVADAS, EN LOS QUE N PUEDE SER 0, 1 O 2; M PUEDE SER 1 O 2, SIEMPRE QUE CUANDO M VALGA 2, ENTONCES N VALGA 1; X CORRESPONDA A UN ENLACE COVALENTE O UN RADICAL BIVALENTE CON LA FORMULA O -, - S -, - NR 3 -; = Q CORRESPONDE A UN = O O = N R 3 ; R 1 CORRESPONDE A UN AR 1 , AR 1 C 1-6 ALQUILO O DI(AR 1 )C 1-6 ALQUILO, EN EL QUE EL GRU PO C 1-6 ALQUILO ESTA OPCIONALMENTE SUSTITUIDO; R 2 CORRESPONDE A UN AR 2 , AR 2 C 1-6 ALQUILO, HET O H ETC 1-6 ALQUILO; L ES UN DERIVADO BENCIMIDAZOL O IMIDAZOLPIRIDINA DE LA FORMULA (A) O (B); AR 1 ESTA OPCIONALMENTE SUSTITUIDO CON UN FENILO; AR 2 CORRESPONDE A UN NAFTALENILO O UN FENILO OPCIONALMENTE SUSTITUIDO; Y HET CORRESPONDE A UN HETEROCICLO MONOCICLICO O BICICLICO OPCIONALMENTE SUSTITUIDO; ACTUAN COMO ANTAGONISTAS DE LA SUSTANCIA P; SU PREPARACION, COMPOSICIONES QUE LOSCONTENGAN Y SU USO COMO MEDICINA.
ES96944686T 1995-12-27 1996-12-20 N-acil-4-piperidinas sustituidas en posicion 2 que tienen restos sustituidos con bencimidazolilo o imidazopiridinilo, como antagonistas de la taquiquinina. Expired - Lifetime ES2166915T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95203653 1995-12-27
EP95203650 1995-12-27

Publications (1)

Publication Number Publication Date
ES2166915T3 true ES2166915T3 (es) 2002-05-01

Family

ID=26139977

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96944686T Expired - Lifetime ES2166915T3 (es) 1995-12-27 1996-12-20 N-acil-4-piperidinas sustituidas en posicion 2 que tienen restos sustituidos con bencimidazolilo o imidazopiridinilo, como antagonistas de la taquiquinina.

Country Status (27)

Country Link
US (1) US6110939A (es)
EP (1) EP0869955B1 (es)
JP (1) JP4177895B2 (es)
KR (1) KR100439846B1 (es)
CN (1) CN1117090C (es)
AR (1) AR005279A1 (es)
AT (1) ATE207484T1 (es)
AU (1) AU707116B2 (es)
BR (1) BR9612326A (es)
CA (1) CA2238816C (es)
CZ (1) CZ294199B6 (es)
DE (1) DE69616379T2 (es)
DK (1) DK0869955T3 (es)
EA (1) EA001247B1 (es)
ES (1) ES2166915T3 (es)
HK (1) HK1012187A1 (es)
HU (1) HU227799B1 (es)
MY (1) MY121580A (es)
NO (1) NO313291B1 (es)
NZ (1) NZ325839A (es)
PL (1) PL184489B1 (es)
PT (1) PT869955E (es)
SI (1) SI0869955T1 (es)
SK (1) SK283533B6 (es)
TR (1) TR199801218T2 (es)
TW (1) TW429256B (es)
WO (1) WO1997024350A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
TW531537B (en) * 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
AU7788500A (en) * 1999-10-25 2001-05-08 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
IL162109A0 (en) 2001-11-23 2005-11-20 Janssen Pharmaceutica Nv The use of anti-histaminics for acute reduction ofelevated intracranial pressure
US20040063744A1 (en) * 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US7348337B2 (en) 2002-05-28 2008-03-25 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
AR044152A1 (es) * 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
JO2676B1 (en) 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
US20060100432A1 (en) 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
DE602006014531D1 (de) 2005-03-03 2010-07-08 Janssen Pharmaceutica Nv Substituierte oxadiazaspiro-ä5.5ü-undecanonderivate und ihre verwendung als neurokininantagonisten
BRPI0608847A2 (pt) 2005-03-08 2010-02-02 Janssen Pharmaceutica Nv derivados de diaza-espiro-[4,4]-nonano substituìdos e seu uso como antagonistas de neurocinina
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
JP2010516734A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンまたはｒ（−）−２，４−ジアミノ−５−（２，３−ジクロロフェニル）−６−フルオロメチルピリミジンを含む医薬組成物
KR20090035279A (ko) * 2007-10-05 2009-04-09 경희대학교 산학협력단 위장관 손상 예방 및 치료용 조성물
ES2936634T3 (es) 2013-02-08 2023-03-21 Gen Mills Inc Productos alimenticios reducidos en sodio

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695575A (en) * 1984-11-13 1987-09-22 Janssen Pharmaceutica, N.V. 4-[(bicycle heterocyclyl)-methyl and -hetero]-piperidines
PH23995A (en) * 1984-01-09 1990-02-09 Janssen Pharmaceutica Nv 4((bicycle heterocyclyl)-methyl and hetero)piperidines
US4835161A (en) * 1986-02-03 1989-05-30 Janssen Pharmaceutica N.V. Anti-histaminic compositions containing n-heterocyclyl-4-piperidinamines
EG17993A (en) * 1986-02-03 1991-08-30 Janssen Pharmaceutica Nv Anti-histaminic compositions containing n-heterocyclyl-4-piperidinanines
US4943580A (en) * 1987-03-09 1990-07-24 Janssen Pharmaceutica N.V. Anti-histaminic benzimidazole, imidazopyridine and purine derivatives
NZ223654A (en) * 1987-03-09 1990-03-27 Janssen Pharmaceutica Nv 1-alkyl-substituted-benzimidazole-4-piperidinamines and pharmaceutical compositions
KR100254666B1 (ko) * 1994-07-15 2000-05-01 이치로 키타사토 혈소판 응집 저해 작용을 갖는 신규 화합물
PT783490E (pt) * 1994-09-30 2002-06-28 Novartis Erfind Verwalt Gmbh Compostos de 1-acil-4-alifatilaminopiperidina
NZ321575A (en) * 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives

Also Published As

Publication number Publication date
EP0869955B1 (en) 2001-10-24
CA2238816C (en) 2006-03-21
BR9612326A (pt) 1999-07-13
HUP9903987A2 (hu) 2000-05-28
HU227799B1 (hu) 2012-03-28
US6110939A (en) 2000-08-29
KR19990076714A (ko) 1999-10-15
KR100439846B1 (ko) 2004-10-22
DE69616379T2 (de) 2002-07-04
PT869955E (pt) 2002-04-29
NO982406D0 (no) 1998-05-27
CN1206414A (zh) 1999-01-27
CZ294199B6 (cs) 2004-10-13
AU707116B2 (en) 1999-07-01
WO1997024350A1 (en) 1997-07-10
NO313291B1 (no) 2002-09-09
DK0869955T3 (da) 2002-02-18
PL184489B1 (pl) 2002-11-29
EP0869955A1 (en) 1998-10-14
MY121580A (en) 2006-02-28
CZ186698A3 (cs) 1998-11-11
TR199801218T2 (xx) 1998-12-21
CN1117090C (zh) 2003-08-06
SK283533B6 (sk) 2003-09-11
HUP9903987A3 (en) 2002-01-28
NZ325839A (en) 1999-05-28
AR005279A1 (es) 1999-04-28
PL327440A1 (en) 1998-12-07
JP4177895B2 (ja) 2008-11-05
HK1012187A1 (en) 1999-07-30
ATE207484T1 (de) 2001-11-15
EA199800602A1 (ru) 1998-12-24
DE69616379D1 (de) 2001-11-29
CA2238816A1 (en) 1997-07-10
AU1308097A (en) 1997-07-28
JP2000502689A (ja) 2000-03-07
NO982406L (no) 1998-08-24
TW429256B (en) 2001-04-11
SK82998A3 (en) 1999-01-11
EA001247B1 (ru) 2000-12-25
SI0869955T1 (en) 2002-04-30

Similar Documents

Publication Publication Date Title
ES2166915T3 (es) N-acil-4-piperidinas sustituidas en posicion 2 que tienen restos sustituidos con bencimidazolilo o imidazopiridinilo, como antagonistas de la taquiquinina.
ES2164939T3 (es) Derivados de 1-(1,2-piperidinil disustituido)-4-piperidina sustituida como antagonistas de receptores de taquicinina.
ES2084944T3 (es) Amidas terapeuticas.
PA8586401A1 (es) 4-piperazinilbencenosulfonilindoles y uso de los mismos
AR025225A1 (es) Feniloxazolidinonas heterociclicas biciclicas sustituidas antibacterianas y composiciones farmacéuticas
UY28764A1 (es) Compuestos poliheterocíclicos y su uso como antagonistas del receptor de glutamato metabotrópico
ES2132351T3 (es) Compuestos con un grupo sulfamoilo y amidino, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
PA8607001A1 (es) Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3
PA8547901A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
UY27446A1 (es) Nuevos compuestos
AR028810A1 (es) Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
ATE485290T1 (de) Platelet adp rezeptor inhibitoren
UY28034A1 (es) Antagonistas de cgrp elegidos, procedimiento para su preparacion asi como su empleo como medicamentos
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
ES2171768T3 (es) Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina.
NO20015502D0 (no) Sulfonamid- og sulfamidsubstituerte imidazokinoliner
BG96961A (bg) Фенилпиразолови производни,фунгицидни състави и използването им за растителна защита
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
SV2005001979A (es) "pirido[2,3-d]pirimidina-2,4-diaminas como inhibidores de pde 2 " ref. pc25123a
PA8803201A1 (es) Derivados acidos de cicloalquilamino
CL2004000590A1 (es) Compuestos derivados de 1,3,4-oxadiazol-3-ona, 1,3,4-tiadiazol-2-ona y de 1,2,4-triazol-3-ona; composicion farmaceutica que los contiene; procedimiento de preparacion y su uso en la preparacion de un medicamento en los que esta relacionado el virus v
PA8654501A1 (es) Derivados de quinazolina inhibidores de quinasas dirigidos a multiples blancos